This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PLC Systems Reports Third Quarter Financial Results

PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today reported financial results for the three and nine months ended September 30, 2012. These results include only the company's RenalGuard ® operations as PLC completed the sale of its transmyocardial revascularization (TMR) business to Novadaq Corp. during the first quarter of 2011. Results from the TMR business are reflected as discontinued operations in the financial results for the nine months ended September 30, 2011. Highlights of the third quarter of 2012 and recent weeks include:
  • Revenues were $212,000, up 685% over the third quarter of 2011
  • Continued patient enrollment for RenalGuard U.S. pivotal trial at 9 trial sites
  • Made progress in Latin America (excluding Brazil where regulatory approval to market has already been obtained) on securing regulatory approvals for RenalGuard marketing on a country-by-country basis
  • Continued to broaden awareness of Contrast-Induced Nephropathy (CIN) with presence at key medical conferences including Latin American Society of Interventional Cardiology 2012 (SOLACI) and Transcatheter Cardiovascular Therapeutics (TCT) 2012
  • Investigators presented their published research on the ability of RenalGuard potentially to reduce the toxic effects of contrast media on the kidneys
  • Secured $1.0 million in financing with another $1.0 million still available based upon achievement of milestones

Management Commentary

“Our efforts to expand awareness of the dangers of CIN are gaining momentum with increasing numbers of key opinion leaders taking to the podium and robust traffic at PLC and distributor booths on exhibition floors,” said Mark R. Tauscher, president and chief executive officer of PLC Systems. “During the quarter, we had a presence at SOLACI where Girlow USA, our distributor in Latin America for all countries except Brazil, exhibited RenalGuard in its booth, demonstrating its ease of use and the supporting clinical studies. In October we had a booth at the all-important TCT meeting, where approximately 60% of the attendees were from countries where RenalGuard is available through distributors. In addition, there was a separate panel discussion at TCT on the prevention of contrast-induced kidney damage with a focus on matched hydration, such as that provided by RenalGuard. The principal investigator of the MYTHOS trial, Dr. Antonio Bartorelli, and the principal investigator of the REMEDIAL II trial, Dr. Carlo Briguori, presented data during the panel discussion.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs